Our Company was originally incorporated as `CORONA Remedies Private Limited', a private limited company, under the Companies Act, 1956, pursuant to a certificate of incorporation dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli. Thereafter, our Company was converted into a public limited company pursuant to a special resolution passed by our Shareholders on October 24, 2024, and consequently, the name of our Company was changed to `CORONA Remedies Limited'. A fresh certificate of incorporation, upon conversion of our Company to a public limited company was issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024.Major events and milestones:2004- Launch of first division, later named as `Pioneer' division in 20102005- Launch of division (multispeciality): Xemx2007- Commencement of production at the first manufacturing plant at Solan, Himachal Pradesh2008- Launch of division (gynaecology): Aarush2013- Launch of division (cardioloy): Wellness2016- Purchased the trademarks "Stelbid" and "Vitneurin" from Glaxo Group Limited- Purchased the trademarks "Dilo DX" and "Dilo-BM" from GlaxoSmithKline Pharmaceuticals Limited2018- Launch of division (cardiovascular diseases): Aura and (gynaecology): Solis- Acquired the trademarks "Obimet", "Obimet-GX", "Obimet SR", "Obimet-V" "Triobimet" and "Thyrocab" (within India) from Abbott India Limited2020- Entered into a strategic alliance with La Chandra Pharmalab Private Limited2021- Commencement of production at the manufacturing plant at Ahmedabad, Gujarat2022- Launch of division (cardiovascular diseases): Radiance and (gynaecology): Solaris2023- Launch of division (urology): Blaze- Purchased the trademark "Myoril" (in India) from Sanofi Healthcare India Private Limited- Received EU GMP accreditation for the manufacturing plant at Ahmedabad, Gujarat 2025 -Acquisition of 7 trademarks from Bayer Zydus Pharma Ltd.